Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma DiveFoundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Lilly bags FDA okay for Wegovy pill rival orforglipronNext: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026